Demographic data |
Demographic data |
Demographic data |
Demographic data |
Demographic data |
Demographic data |
Demographic data |
Comorbidities |
Comorbidities |
Comorbidities |
Comorbidities |
Comorbidities |
Comorbidities |
Asthma
treatment |
Asthma treatment |
Asthma treatment |
Asthma treatment |
Asthma treatment |
Asthma
treatment |
IRSA center id. |
Region |
Province |
Pt. ID |
Sex |
Age |
BMI |
Smoking (active) |
Hypertension |
Nasal
polyps |
Bronchiectasis |
GERD |
Comorbidities (n.) |
Treatment |
Add-on
biologic drug |
COVID-19 severity |
COVID-19 severity |
COVID-19 severity |
ICU admission |
25 |
E-R |
R. Emilia |
1 |
F |
48 |
32.1 |
No |
No |
No |
No |
No |
1
(Obesity) |
ICS+LABA |
Omalizumab |
Home care |
Home care |
Home care |
- |
40 |
Lombardy |
Bergamo |
2 |
F |
65 |
24.5 |
No |
Yes |
No |
No |
No |
1 |
ICS+LABA+OCS |
Omalizumab |
Hospitalized |
Hospitalized |
Hospitalized |
No |
46 |
Lombardy |
Milan |
3 |
F |
40 |
29 |
No |
No |
Yes |
Yes |
No |
2 |
ICS+LABA+LAMA |
Mepolizumab |
Home care |
Home care |
Home care |
- |
102 |
Lombardy |
Cremona |
4 |
F |
51 |
25.2 |
No |
No |
Yes |
Yes |
No |
2 |
ICS+LABA+LAMA |
Omalizumab |
Home care |
Home care |
Home care |
- |
114 |
Lombardy |
Brescia |
5 |
F |
57 |
22.3 |
No |
Yes |
Yes |
Yes |
No |
3 |
ICS+LABA+LAMA |
Mepolizumab |
Hospitalized |
Hospitalized |
Hospitalized |
No |
114 |
Lombardy |
Brescia |
6 |
M |
65 |
26.1 |
No |
No |
No |
No |
Yes |
1 |
ICS+LABA+LAMA |
Mepolizumab |
Home care |
Home care |
Home care |
- |
114 |
Lombardy |
Brescia |
7 |
F |
56 |
17.9 |
No |
No |
Yes |
No |
No |
1 |
ICS+LABA |
Mepolizumab |
Home care |
Home care |
Home care |
- |
Average |
- |
- |
- |
- |
54.6 |
25.3 |
- |
- |
- |
- |
- |
1.6 |
- |
- |
- |
- |
- |
- |
SD |
- |
- |
- |
- |
8.4 |
4.2 |
- |
- |
- |
- |
- |
0.7 |
- |
- |
- |
- |
- |
- |